We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: IL-6
MedXY News
EnglishTag

IL-6

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating the ISOLD Score for Accurate Diagnosis of Vitreoretinal Lymphoma in Clinical Practice
Hematology-OncologyAqueous humorIL-10

Evaluating the ISOLD Score for Accurate Diagnosis of Vitreoretinal Lymphoma in Clinical Practice

By MedXY|Jul 9, 2026

This study validates the ISOLD score, a cytokine-based probabilistic tool, demonstrating high sensitivity and specificity for diagnosing vitreoretinal lymphoma from aqueous humor samples, outperforming standard IL-10/IL-6 ratios, with impli

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank
CardiologyAortic Valve Stenosiscoronary artery disease

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY|Jun 27, 2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker
newsesophageal squamous cell carcinomaIL-6

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker

By MedXY|Dec 9, 2025

The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po

Nature: Influenza and SARS‑CoV‑2 can awaken dormant breast cancer cells and trigger lung metastasis
Clinical Updatescancer recurrenceIL-6

Nature: Influenza and SARS‑CoV‑2 can awaken dormant breast cancer cells and trigger lung metastasis

By MedXY|Oct 2, 2025

A Nature paper shows influenza and SARS‑CoV‑2 lung infections can reactivate dormant disseminated breast cancer cells (DCCs) via IL‑6 and CD4+ T‑cell–mediated mechanisms, with concordant human data linking SARS‑CoV‑2 infection to higher can

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story